Drugs / PAC113
last change Jun 2008 re-read 3 minutes ago

PAC113

Developed for
oral candidiasis
Investigated by
Pacgen Biopharmaceuticals Corporation · Quintiles, Inc.

Trials 1

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00659971 Jan → Jun 2008 oral candidiasis Pacgen Biopharmaceuticals Corporation Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as PAC113 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00659971 ↗